| Project/Area Number |
18K14951
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 小児・新生児 / 抗MRSA薬 / 治療薬物モニタリング / ファーマコメトリクス |
|---|
| Outline of Final Research Achievements |
In this study, we developed a teicoplanin population pharmacokinetic model and a physiologically-based pharmacokinetic model in children and neonates. We also proposed new optimal dosing regimens for teicoplanin and evaluated the application in clinical setting. Body weight, postmenstrual age, renal function, and serum albumin were implemented as substantial covariates for teicoplanin clearance. In addition, the simulation analysis identified neonates and children who required dose adjustment from the standard doses. These results may lead to provide optimized teicoplanin doses, as well as the standardization of dosing for children and neonates.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、これまで医薬品開発で利用されてきたファーマコメトリクスを小児・新生児領域における臨床ファーマコメトリクスとして新たに活用したことを特徴としている。得られた研究成果は、小児・新生児におけるテイコプラニンの個別化投与ならびに投与設計の標準化につながり、血中濃度の測定が困難な施設においても利用可能となることが期待される。また、メチシリン耐性黄色ブドウ球菌感染症の治療向上、有害反応の回避という側面からも、意義深い研究であると考えられる。
|
